Off Targets develops complex injectable, sterile, and advanced-delivery formulations from known molecules — engineering the kind of formulation complexity that creates real clinical and commercial differentiation, and real barriers to entry.
Injectable figure reflects active pipeline programs across long-acting injectables, pre-filled syringes, ready-to-use, lyophilised and emulsion products. Oral solids reflects products developed to date.
By focusing on known molecules with defined regulatory pathways, we design out the largest sources of early-stage failure before development even begins.
Rigorous product selection and stage-gated development keep capital focused only on products with real regulatory and commercial feasibility.
Complex injectables, long-acting and lipid-based delivery, lyophilisation, and other advanced dosage forms create genuine clinical and commercial barriers to entry.
The investment thesis and our two-hub operating model across the UK and India.
Explore →02A six-stage path from concept to commercial supply, with regulatory execution built in.
Explore →03We front the investment and carry development risk, so partners receive de-risked assets.
Explore →04The delivery technologies where formulation complexity creates the barrier to entry.
Explore →05Access, affordability and quality of healthcare delivered through better formulations.
Explore →06Portfolio composition and maturity, with program detail reserved for qualified partners.
Explore →07Leadership experience, organizational depth across every discipline, and a KOL and SME network.
Explore →08How we engage on licensing, co-development and co-investment, plus common questions.
Explore →09Formulations we have delivered and the partnership models we have operated.
Explore →